News Conference News ACC 2025 Low-Dose Apixaban Prevents Recurrent VTE in Cancer Beyond 6 Months: API-CAT Caitlin E. Cox March 29, 2025
News Opinion Editor's Corner ACC 2025 What’s Going to Be Hot at ACC 2025? Michael O'Riordan March 26, 2025
News Conference News ACC 2020 New Questions About Triple Therapy After PAD Revascularization: VOYAGER PAD Substudy L.A. McKeown April 02, 2020
News Conference News ACC 2017 ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More Shelley Wood March 10, 2017